Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about dealing with hair loss during university, with the original poster using dutasteride and minoxidil as treatments. Participants share their experiences and coping strategies, such as wearing hats, considering going completely bald, or getting a hair transplant after graduation.

Maximum serum DHT suppression for finasteride occurs at 8 hours, while for dutasteride, it occurs within 1 to 2 weeks with daily dosing. Dutasteride mesotherapy will be followed by blood tests to check serum DHT changes.

The conversation is about managing allopregnanolone deficiency caused by 5-alpha-reductase inhibitors like finasteride or dutasteride. Specific treatments discussed for hair loss include Minoxidil, finasteride, and RU58841.

The conversation is about someone inquiring if anyone has tried Olumiant or its active ingredient, Baricitinib, for hair loss, mentioning the cost and that they have ordered Baricitinib.

An 18-year-old male switched from topical finasteride and minoxidil to oral dutasteride for diffuse hair loss and saw improvement without side effects, despite experiencing scalp itch and shedding. Commenters noted significant hair regrowth and were surprised by his young age and appearance.

Discussion on hair loss treatments, focusing on Breezula, with mentions of Minoxidil, finasteride, RU58841, Pyrilutamide, GT20029, and PP405. Breezula's effectiveness is uncertain, with some trials showing minimal regrowth.

Switching generic finasteride manufacturers can reduce side effects while maintaining effectiveness. Different fillers in generics may affect bioavailability and cause varying side effects.

The conversation humorously discusses the use of pp405 for hair loss, with mentions of finasteride and minoxidil. Users joke about unusual side effects like growing extra body parts.

The conversation discusses hair loss treatments, specifically seeking a 15% glycyrrhizic acid formula without additional ingredients. It also mentions the potential opposite effects of glycyrrhizic acid on humans compared to rats.

The conversation is about using adenosine, finasteride, and minoxidil for hair loss treatment. The user ordered a 0.75% adenosine solution and is currently using finasteride 1mg and minoxidil 5%.

Orient Bio is developing a PLGA formulated version of Cyclosporine A to stimulate hair growth without its immunosuppressant effects. Users discuss various treatments like Clascoterone, PP405, minoxidil, and tacrolimus, expressing hope for new developments and sharing personal experiences with these treatments.

OP reports minimal shedding and improved hair thickness after nearly 3 months on a combination of dutasteride and minoxidil. Users discuss realistic expectations, hair density improvement, and the cost of branded versus generic medications.

A user traveled to Turkey to buy 72 packages of Dutasteride for a year-long supply and successfully brought them back home. They plan to use 2.5mg of Dutasteride daily along with RU58841 for hair loss.

The conversation discusses concerns about using a high concentration of 1% topical finasteride for hairline balding, with some users suggesting starting with a lower dose. It also mentions the use of GHK-CU peptide and the importance of considering the formulation to avoid excessive absorption.

The conversation discusses using a combination of finasteride, spironolactone, minoxidil, retinol, azelaic acid, and caffeine for hair loss treatment. The user inquires about the limitations of these drugs and whether tretinoin would be more effective than retinol.

The user discusses their hair loss experience, exploring various hypotheses including thyroid levels, vitamin D, DHEA, nutritional deficiency, diabetes, seborrheic dermatitis, lack of nutrition to hair follicles, chronic inflammation, female pattern hair loss causes, cortisol, and prolactin levels. They are currently using finasteride, beta-sitosterol, and have tried topical dutasteride and microneedling therapy.

KX-826 combined with minoxidil significantly increases hair growth compared to minoxidil alone for treating male androgenetic alopecia, with no unexpected safety concerns. Users discuss various hair loss treatments, including KX-826, minoxidil, finasteride, and RU58841, sharing personal experiences and sourcing information.

The user is documenting their hair loss progress using 0.5mg oral dutasteride daily. They shared pictures and received encouragement.

Astaxanthin may cause increased hair shedding, affecting even transplanted hair and eyebrows. The user has tried various treatments for androgenic alopecia, including minoxidil, finasteride, and RU58841.

The conversation discusses hair loss treatments, including finasteride, microneedling, minoxidil, and PTD-DBM. The user has not noticed significant regrowth and is considering cost-effective options like valproic acid.

Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.

The user resumed using topical finasteride after a two-week break and will update on side effects like water retention and gynecomastia in a month. They are also starting DIM and zinc.

A peptide-based delivery system for finasteride shows promise in reducing systemic side effects while maintaining hair growth effectiveness. Combining this with other treatments like minoxidil and RU58841 could enhance results with lower systemic absorption.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

The user's hair appears to have improved, looking thicker and healthier, especially around the temples, after using topical minoxidil, finasteride, dutasteride, and tretinoin. Most participants agree the last picture shows significant improvement, though one disagrees.

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.

Oral minoxidil combined with isotretinoin may improve hair loss treatment effectiveness. Tretinoin is known to increase the absorption of topical minoxidil.

The conversation is about a user planning a blood test to monitor health while on hair loss treatments: Finasteride, Minoxidil, and Dutasteride. Recommendations include testing for androgens, thyroid function, micronutrients, and basic health markers, with additional suggestions for PSA, prolactin, and estradiol.

The conversation discusses the completion of a Phase II trial recruitment for Breezula (CB-03-01), a potential treatment for androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

The conversation is about a user's hair loss treatment routine, which includes RU58841 for 9 months and Dutasteride for 6 months, with other unspecified treatments considered extra. One user inquired about the source of RU58841.